The University of Southampton
University of Southampton Institutional Repository

Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid

Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
Glycinamide ribonucleotide transformylase (GAR Tfase) has been the target of anti-neoplastic intervention for almost two decades. Here, we use a structure-based approach to design a novel folate analogue, 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid (10-CF(3)CO-DDACTHF, 1), which specifically inhibits recombinant human GAR Tfase (K(i) = 15 nM), but is inactive (K(i) > 100 microM) against other folate-dependent enzymes that have been examined. Moreover, compound 1 is a potent inhibitor of tumor cell proliferation (IC(50) = 16 nM, CCRF-CEM), which represents a 10-fold improvement over Lometrexol, a GAR Tfase inhibitor that has been in clinical trials. Thus, this folate analogue 1 is among the most potent and selective inhibitors known toward GAR Tfase. Contributing to its efficacious activity, compound 1 is effectively transported into the cell by the reduced folate carrier and intracellularly sequestered by polyglutamation. The crystal structure of human GAR Tfase with folate analogue 1 at 1.98 A resolution represents the first structure of any GAR Tfase to be determined with a cofactor or cofactor analogue without the presence of substrate. The folate-binding loop of residues 141-146, which is highly flexible in both Escherichia coli and unliganded human GAR Tfase structures, becomes highly ordered upon binding 1 in the folate-binding site. Computational docking of the natural cofactor into this and other apo or complexed structures provides a rational basis for modeling how the natural cofactor 10-formyltetrahydrofolic acid interacts with GAR Tfase, and suggests that this folate analogue-bound conformation represents the best template to date for inhibitor design.
binding sites cell line crystallography, x-ray drug design electrostatics enzyme inhibitors/chemical synthesis, chemistry, pharmacology escherichia coli/enzymology humans hydroxymethyl and formyl transferases, antagonists & inhibitors/chemistry kinetics macromolecular substances models, molecular nuclear magnetic resonance, biomolecular phosphoribosylglycinamide formyltransferase protein conformation recombinant proteins/antagonists & inhibitors/chemistry tetrahydrofolates/chemical synthesis, pharmacology
0006-2960
6043-6056
Zhang, Y.
f812509d-2a3c-41aa-8ba1-68210952d5a6
Desharnais, J.
d5a6615b-0e18-4abb-854c-87193e7bbd96
Marsilje, T.H.
cd3f3685-e115-4719-9b07-8a0b5b6ab40c
Li, C.L.
c27634b9-406b-47ee-afa9-401cbbd0d9db
Hedrick, M.P.
396aa06c-ee47-4b43-8b3a-6d17a7179664
Gooljarsingh, L.T.
5de50e85-6ab6-4b96-97ec-dfafd5a3cb62
Tavassoli, A.
d561cf8f-2669-46b5-b6e1-2016c85d63b2
Benkovic, S.J.
1423c0c2-678d-4968-a05d-4c303e81047d
Olson, A.J.
3edf1fb5-297d-4df0-abe4-89fd45274ef0
Boger, D.L.
5af3cbf4-1b2a-40cf-9faf-81ecdcc238ec
Wilson, I.A.
845971ad-12b6-4752-9eea-4ce5092284ab
Zhang, Y.
f812509d-2a3c-41aa-8ba1-68210952d5a6
Desharnais, J.
d5a6615b-0e18-4abb-854c-87193e7bbd96
Marsilje, T.H.
cd3f3685-e115-4719-9b07-8a0b5b6ab40c
Li, C.L.
c27634b9-406b-47ee-afa9-401cbbd0d9db
Hedrick, M.P.
396aa06c-ee47-4b43-8b3a-6d17a7179664
Gooljarsingh, L.T.
5de50e85-6ab6-4b96-97ec-dfafd5a3cb62
Tavassoli, A.
d561cf8f-2669-46b5-b6e1-2016c85d63b2
Benkovic, S.J.
1423c0c2-678d-4968-a05d-4c303e81047d
Olson, A.J.
3edf1fb5-297d-4df0-abe4-89fd45274ef0
Boger, D.L.
5af3cbf4-1b2a-40cf-9faf-81ecdcc238ec
Wilson, I.A.
845971ad-12b6-4752-9eea-4ce5092284ab

Zhang, Y., Desharnais, J., Marsilje, T.H., Li, C.L., Hedrick, M.P., Gooljarsingh, L.T., Tavassoli, A., Benkovic, S.J., Olson, A.J., Boger, D.L. and Wilson, I.A. (2003) Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid. Biochemistry, 42 (20), 6043-6056. (doi:10.1021/bi034219c).

Record type: Article

Abstract

Glycinamide ribonucleotide transformylase (GAR Tfase) has been the target of anti-neoplastic intervention for almost two decades. Here, we use a structure-based approach to design a novel folate analogue, 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid (10-CF(3)CO-DDACTHF, 1), which specifically inhibits recombinant human GAR Tfase (K(i) = 15 nM), but is inactive (K(i) > 100 microM) against other folate-dependent enzymes that have been examined. Moreover, compound 1 is a potent inhibitor of tumor cell proliferation (IC(50) = 16 nM, CCRF-CEM), which represents a 10-fold improvement over Lometrexol, a GAR Tfase inhibitor that has been in clinical trials. Thus, this folate analogue 1 is among the most potent and selective inhibitors known toward GAR Tfase. Contributing to its efficacious activity, compound 1 is effectively transported into the cell by the reduced folate carrier and intracellularly sequestered by polyglutamation. The crystal structure of human GAR Tfase with folate analogue 1 at 1.98 A resolution represents the first structure of any GAR Tfase to be determined with a cofactor or cofactor analogue without the presence of substrate. The folate-binding loop of residues 141-146, which is highly flexible in both Escherichia coli and unliganded human GAR Tfase structures, becomes highly ordered upon binding 1 in the folate-binding site. Computational docking of the natural cofactor into this and other apo or complexed structures provides a rational basis for modeling how the natural cofactor 10-formyltetrahydrofolic acid interacts with GAR Tfase, and suggests that this folate analogue-bound conformation represents the best template to date for inhibitor design.

This record has no associated files available for download.

More information

Published date: 2003
Keywords: binding sites cell line crystallography, x-ray drug design electrostatics enzyme inhibitors/chemical synthesis, chemistry, pharmacology escherichia coli/enzymology humans hydroxymethyl and formyl transferases, antagonists & inhibitors/chemistry kinetics macromolecular substances models, molecular nuclear magnetic resonance, biomolecular phosphoribosylglycinamide formyltransferase protein conformation recombinant proteins/antagonists & inhibitors/chemistry tetrahydrofolates/chemical synthesis, pharmacology
Organisations: Chemistry

Identifiers

Local EPrints ID: 45310
URI: http://eprints.soton.ac.uk/id/eprint/45310
ISSN: 0006-2960
PURE UUID: 9f8341b1-386d-42e7-9a01-b69e35e5f4b9
ORCID for A. Tavassoli: ORCID iD orcid.org/0000-0002-7420-5063

Catalogue record

Date deposited: 20 Mar 2007
Last modified: 16 Mar 2024 03:51

Export record

Altmetrics

Contributors

Author: Y. Zhang
Author: J. Desharnais
Author: T.H. Marsilje
Author: C.L. Li
Author: M.P. Hedrick
Author: L.T. Gooljarsingh
Author: A. Tavassoli ORCID iD
Author: S.J. Benkovic
Author: A.J. Olson
Author: D.L. Boger
Author: I.A. Wilson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×